At a Glance
Tarsons Products Ltd (TPL) is India’s labware darling, making plastic consumables, reusables, and benchtop lab equipment. The company sells to pharma, research, and diagnostic labs—a recession-proof sector, theoretically. But the stock trades at a P/E of 67, while profits are shrinking faster than agar plates in the sun. Margins have fallen, debt has ballooned, and promoters haven’t increased their stake. Yet, investors are clinging to the biotech growth story like a lab intern to their first pipette.
Introduction
Labware may sound boring, but it’s a critical business—without consumables, labs can’t function. Tarsons has long been a domestic leader with a strong portfolio and recent international acquisitions (Nerbe GmbH in Germany). However, the fairy tale is losing its sparkle: margins have compressed, ROE has dropped below 5%, and debt is rising thanks to expansion at Panchla and overseas subsidiaries.
Despite this, the market keeps the stock expensive, probably because “life sciences” sounds futuristic. Investors may need to check whether the current valuation is science or pure science fiction.
Business Model (WTF Do They Even Do?)
Tarsons makes:
- Consumables: plastic lab items (pipette tips, centrifuge tubes).
- Reusables: bottles, carboys, measuring cylinders.
- Others: benchtop equipment (vortex mixers, centrifuges).
Customers include pharmaceutical companies, research institutes, CROs, and diagnostic labs.
